• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,034.42 -829.29
( -1.08%)
Global Indices
Nasdaq
47,431.94 -295.58
(-0.62%)
Dow Jones
6,795.43 -7.05
(-0.10%)
Hang Seng
54,230.47 -794.90
(-1.44%)
Nikkei 225
10,315.38 -96.86
(-0.93%)
Forex
USD-INR
91.90 -0.24
(-0.26%)
EUR-INR
106.87 0.29
(0.27%)
GBP-INR
123.51 0.42
(0.34%)
JPY-INR
0.58 0.00
(0.09%)

EQUITY - MARKET SCREENER

Vilin Bio Med Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
78871
INE0L4V01013
16.5329749
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VILINBIO
216.56
48.34
EPS(TTM)
Face Value()
Div & Yield %
0.16
10
0
 

NBCC arm signs MoU with BEL for healthcare collaboration
Jan 13,2026
The collaboration will cover manufacturing and supply of medical devices, healthcare IT and digital solutions, consultancy, project execution, joint procurement, AMC and warranty support, and related advisory services. Project-specific agreements will be executed separately.

The company clarified that the MoU has been entered into in the normal course of business of the subsidiary.

NBCC (India) is in business and operates in three major segments, namely project management consultancy, real estate, and engineering procurement & construction.

The company's consolidated net profit advanced 25.21% to Rs 156.68 crore on an 18.99% rise in revenue from operations to Rs 2,910.19 crore in Q2 FY26 over Q2 FY25.

Shares of NBCC (India) fell 1.67% to Rs 105.85 on the BSE.